Acknowledgment and Consent for Disclosure of
Section 712(c)(2)(B) of the Federal Food, Drug, and Cosmetic Act
And 18 U.S.C. §208
Particular Matter Waiver

Advisory Committee Member: Mark Ballow, M.D.

Committee: Blood Products Advisory Committee

Meeting Date: May 2, 2008

I acknowledge that contingent upon public disclosure of the following financial interest submitted on my FDA Form 3410 and related to the agenda item: Lev Pharmaceuticals' plasma derived C1 esterase inhibitor, I am eligible to receive a particular matter waiver under Section 712(c)(2)(B) and 18 U.S.C. §208.

Type of Interest	Nature	Magnitude
Consulting	Competing firm	Less than $10,000

I hereby request that FDA make this information publicly available on my behalf at the start of the advisory committee meeting for which it is issued by reading this acknowledgment into the record. I understand that without public disclosure of the interests the waiver is not valid.

/s/
Mark Ballow, M.D.

3/6/08
Date